News

April 20, 2017

Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting
INDIANAPOLIS, April 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston. Lilly will present four abstracts at AAN, including safety and patien...

April 14, 2017

U.S. FDA Issues Complete Response Letter for Baricitinib
INDIANAPOLIS--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication ...

April 7, 2017

Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences
INDIANAPOLIS, ARLINGTON, Va. and ROLLING MEADOWS, Ill., April 7, 2017 /PRNewswire/ -- Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To help support people with diabetes and those who love them, Lilly Diabe...

March 23, 2017

Lilly and the William Sansum Diabetes Center announce a five-year research collaboration
SANTA BARBARA, Calif. and INDIANAPOLIS, March 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, education and care. "The tremendous burden of diabetes and cardiovascu...

March 20, 2017

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
INDIANAPOLIS, March 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-rece...

March 17, 2017

First dedicated outcome trials of empagliflozin in chronic heart failure initiated
RIDGEFIELD, Conn. and INDIANAPOLIS, March 17, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the EMPEROR HF clinical trial program was initiated. EMPEROR HF comprises two phase III outcome studies that will investigate empagliflozin for the treatment of adults with chronic heart failure. The tri...

March 4, 2017

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis
Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) ...

March 3, 2017

Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®'
DAYTONA BEACH, Fla., March 3, 2017 /PRNewswire/ -- NASCAR® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body. The new collaboration designates Lilly Diabetes as the "Official Diabetes Health Partner of NASCAR." The partnership with Lilly...

February 28, 2017

Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting
INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017, in O...

February 15, 2017

Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
INDIANAPOLIS, Feb. 15, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - were published in the New England Journal of Medicine. The New Engla...

February 13, 2017

European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-...

February 8, 2017

Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- The label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. The U.S. Food and Drug Administration (FDA) included the changes to the approved product labeling to reflect this impo...

January 13, 2017

U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
INDIANAPOLIS, Jan. 13, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumato...

January 11, 2017

Lilly and Merck Expand Immuno-Oncology Collaboration
INDIANAPOLIS, Jan. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, through a subsidiary, to add a new study of Lilly's LARTRUVO™ (olaratumab) with KEYTRUDA® (pembrolizumab) in patients with previousl...

January 4, 2017

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linagliptin) tablets
RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 4, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME® trial. The data show that empagliflozin reduced the risk for cardiovascu...

December 16, 2016

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ -- The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of Jardiance® (empagliflozin) tablets in people with type 2 diabetes and established cardiovascular disease to reduce the risk of ca...

December 16, 2016

CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)
INDIANAPOLIS, Dec. 16, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib - which if approved would be marketed as Olumiant®....

December 15, 2016

BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.
INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. announced today that BASAGLAR® (insulin glargine injection 100 units/mL) is available by prescription in the U.S. BASAGLAR is a follow-on insulin to Lantus®. It is a long-acting insulin with an...

December 13, 2016

Lilly Announces Program to Provide Insulin at Discounted Prices
INDIANAPOLIS, Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January 1, 2017 via mobile and web platforms hosted by Blink Health. The discounts, provided by Lilly through a partnership with Express Scripts (NASDAQ...

December 12, 2016

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with type...

Showing 1-20 of 31 Page: 1 2  Next 20